Výsledky vyhledávání - "Jamie Arnott"

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

Autor: Ursula A. Matulonis, Helen Mackay, C. Sidor, Nita K. Lee, Brian Lasonde, Gini F. Fleming, Vincent Castonguay, Julie Lee, Amit M. Oza, Jamie Arnott, Graham C. Fletcher, Daniela Matei, Mark R. Bray, Jill Grothusen, William P. Tew, Richard Brokx, Kian Behbakht, Afra Yehwalashet

Publikováno v: European Journal of Cancer. 49:121-131

Purpose The purpose was to assess the activity and side effect profile of ENMD-2076, an oral anti-angiogenic and anti-proliferative kinase inhibitor, in platinum-resistant recurrent epithelial ovarian cancer (EOC), fallopian tube or peritoneal cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7412cb99116abce0a01a84bb24f4c028
https://doi.org/10.1016/j.ejca.2012.07.020

Zobrazit plný text záznamu

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia

Autor: David W. Hedley, Mark D. Minden, Joseph Brandwein, Lisa W. Le, Jamie Arnott, Aaron D. Schimmer, Deborah Sanfelice, Karen W.L. Yee, Mark R. Bray, Sue Chow, Andre C. Schuh, Tara Johnson, C. Sidor, Hsiao-Wei T. Chen, Vikas Gupta

Publikováno v: Investigational new drugs. 34(5)

ENMD-2076 is a novel, orally-active molecule that inhibits Aurora A kinase, as well as c-Kit, FLT3 and VEGFR2. A phase I study was conducted to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D) and toxicities of ENMD-2076 in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292aeb0c3b4135f768a07a7903b889cf
https://pubmed.ncbi.nlm.nih.gov/27406088

Zobrazit plný text záznamu

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Autor: Todd M. Pitts, Graham C. Fletcher, S. Gail Eckhardt, E. L. Kwak, Jennifer R. Diamond, Ryan J. Hansen, Wells A. Messersmith, Gillian N. Kulikowski, Jamie Arnott, C. Sidor, Bruno R. Bastos, Shuchi Sumant Pandya, Daniel L. Gustafson, Mark Morrow, Mark R. Bray, Geoffrey I. Shapiro

Publikováno v: Clinical Cancer Research. 17:849-860

Purpose: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles and preliminary antitumor activity. Experimen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::529b05db36a3fce5f0a6f8919a5cf87d
https://doi.org/10.1158/1078-0432.ccr-10-2144

Zobrazit plný text záznamu

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design

Autor: William R. Schelman, Jens C. Eickhoff, George Wilding, Glenn Liu, Jamie Arnott, Rick Chappell, C. Sidor, Amye J. Tevaarwerk, Howard H. Bailey

Publikováno v: Investigational New Drugs. 30:1039-1045

Background MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies demonstrated modest antitumor activity using intermittent dosing schedule, however additional preclinical data suggested continuous

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afcdfd9d117c43ca00b3c5c4fac208ed
https://doi.org/10.1007/s10637-010-9629-6

Zobrazit plný text záznamu

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Autor: Jamie Arnott, Jens C. Eickhoff, Michael A. Carducci, Anthony M. Treston, Justine Yang Bruce, George Wilding, Roberto Pili, Glenn Liu, Theodore F. Logan

Publikováno v: Investigational New Drugs. 30:794-802

Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete responses are rare. We conducted a multicenter phase I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ec510dad140ea56786328d236fd3f0
https://doi.org/10.1007/s10637-010-9618-9

Zobrazit plný text záznamu

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Autor: Scott B. Perlman, Jamie Arnott, Michael R. Harrison, Kyung Mann Kim, William Oh, Hans J. Hammers, Roberto Pili, George Wilding, Noah M. Hahn, Glenn Liu, Christopher Sweeney, C. Sidor

Publikováno v: Investigational New Drugs. 29:1465-1474

Purpose: 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with ta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8771adc214d523446c314f3fb922c516
https://doi.org/10.1007/s10637-010-9455-x

Zobrazit plný text záznamu

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

Autor: C. Sidor, Check Quon, Glenn Liu, George Wilding, Amye J. Tevaarwerk, Dona Alberti, Jamie Arnott, Kyle D. Holen

Publikováno v: Clinical Cancer Research. 15:1460-1465

Purpose: 2-Methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17β metabolite that at pharmacologic doses exerts antimitotic and antiangiogenic activities. Studies with a 2ME2 capsule formulation showed limited oral bioavailability. We repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66e9375d2593dae733448d479ac65bdc
https://doi.org/10.1158/1078-0432.ccr-08-1599

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání